A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia.

ABSTRACT:

Background

Longer-term pharmacologic studies for insomnia in older individuals are sparse.

Objective

To evaluate the efficacy and safety of 12 weeks of nightly eszopiclone in elderly outpatients with insomnia.

Methods

Participants (65-85 years) met DSM-IV-TR criteria for insomnia with total sleep times (TST) < or = 6 h, and wake time after sleep onset (WASO) > or = 45 min. Participants were randomized to 12 weeks of eszopiclone 2 mg (n = 194) or placebo (n = 194), followed by a 2-week single-blind placebo run-out. Subject-reported measures of sleep (sTST, sleep latency [sSL], sWASO) and daytime function (alertness, concentration, wellbeing, ability to function) were assessed. AEs were monitored.

Results

Subjects treated with 2 mg eszopiclone slept longer at nig

SUBMITTER: Ancoli-Israel S 

PROVIDER: S-EPMC2817909 | biostudies-literature | 2010 Feb

REPOSITORIES: biostudies-literature